Who owns ATHIRA PHARMA INC?
- Ticker: ATHA
- CUSIP Number: 04746l104
Tip: Access positions for across all investors
Analyze quarterly positions in Athira Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Athira Pharma stock
Who bought or sold ATHIRA PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Perceptive Advisors | 5.4M | $15M | 0% | Mar 2024 |
|
| Baker Bros. Advisors | 3.2M | $8.6M | 0% | Mar 2024 |
|
| Vanguard Group | 1.6M | $4.5M | -4% | Mar 2024 |
|
| Simplify Asset Management | 1.5M | $4.1M | 0% | Mar 2024 |
|
| Propel Bio Management | 1.5M | $4.1M | 0% | Mar 2024 |
|
| BML Capital Management | 900k | $2.5M | -38% | Mar 2024 |
|
| Tang Capital Management | 853k | $2.3M | -26% | Mar 2024 |
|
| BlackRock | 667k | $1.8M | 1% | Mar 2024 |
|
| Acadian Asset Management | 550k | $1.5M | 294% | Mar 2024 |
|
| Jacobs Levy Equity Management | 498k | $1.4M | 84% | Mar 2024 |
|
| Pathstone Holdings | 492k | $1.3M | 32% | Mar 2024 |
|
| Dimensional Fund Advisors | 439k | $1.2M | 26% | Mar 2024 |
|
| Two Sigma Investments | 426k | $1.2M | 40% | Mar 2024 |
|
| Two Sigma Advisers | 370k | $1.0M | 24% | Mar 2024 |
|
| Geode Capital Management | 300k | $823k | 6% | Mar 2024 |
|
| Bank of America Corporation | 228k | $626k | 369% | Mar 2024 |
|
| Susquehanna International | 199k | $544k | 112% | Mar 2024 |
|
| GSA Capital Partners | 176k | $483k | -41% | Mar 2024 |
|
| Bridgeway Capital Management | 176k | $482k | -5% | Mar 2024 |
|
| Advisor Group Holdings | 164k | $448k | -4% | Mar 2024 |
|
| Potomac Capital Management | 150k | $364k | 101% | Dec 2023 |
|
| Laird Norton Tyee Trust | 147k | $404k | -18% | Mar 2024 |
|
| Jane Street | 147k | $402k | 544% | Mar 2024 |
|
| Millennium Management | 142k | $388k | -69% | Mar 2024 |
|
| Barclays | 132k | $361k | -24% | Mar 2024 |
|
| Citadel Advisors | 122k | $335k | -67% | Mar 2024 |
|
| Bristlecone Advisors | 85k | $234k | 0% | Mar 2024 |
|
| CornerCap Investment Counsel | 75k | $207k | 0% | Mar 2024 |
|
| Clarius | 54k | $147k | 0% | Mar 2024 |
|
| Northern Trust | 53k | $146k | -2% | Mar 2024 |
|
| Morgan Stanley | 43k | $115k | -32% | Mar 2024 |
|
| Occudo Quantitative Strategies | 42k | $115k | 170% | Mar 2024 |
|
| Bailard | 41k | $111k | 100% | Mar 2024 |
|
| Goldman Sachs Group | 40k | $110k | 100% | Mar 2024 |
|
| William Blair $ Company | 36k | $99k | 0% | Mar 2024 |
|
| American Century Companies | 36k | $98k | 133% | Mar 2024 |
|
| Levin Easterly Partners | 34k | $92k | 0% | Mar 2024 |
|
| Integrity Financial Corp | 33k | $90k | 0% | Mar 2024 |
|
| Brighton Jones | 32k | $88k | 100% | Mar 2024 |
|
| Springbok Capital Management | 24k | $65k | -26% | Mar 2024 |
|
| Qube Research & Technologies | 21k | $58k | 357% | Mar 2024 |
|
| Mirador Capital Partners | 21k | $57k | 100% | Mar 2024 |
|
| Forefront Analytics | 21k | $57k | -1% | Mar 2024 |
|
| Massey, Quick & Co | 21k | $56k | 0% | Mar 2024 |
|
| Journey Strategic Wealth | 21k | $56k | 0% | Mar 2024 |
|
| Sargent Investment Group | 20k | $54k | 9% | Mar 2024 |
|
| Simplex Trading | 18k | $50k | 100% | Mar 2024 |
|
| Ameriprise Financial | 18k | $50k | 19% | Mar 2024 |
|
| Point72 Asia | 18k | $49k | 477% | Mar 2024 |
|
| Federated Investors | 14k | $34k | -6% | Dec 2023 |
|
| Lindbrook Capital | 13k | $35k | 31% | Mar 2024 |
|
| HighTower Advisors | 13k | $34k | 0% | Mar 2024 |
|
| Cambridge Investment Research Advisors | 12k | $32k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 11k | $30k | -35% | Mar 2024 |
|
| FRG Family Wealth Advisors | 9.2k | $18k | 100% | Mar 2024 |
|
| Group One Trading | 9.1k | $25k | 100% | Mar 2024 |
|
| Ohio Pers | 8.3k | $23k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 8.1k | $22k | -77% | Mar 2024 |
|
| Jpmorgan Chase & Co | 7.5k | $21k | 5171% | Mar 2024 |
|
| Tower Research Capital | 4.6k | $13k | 2714% | Mar 2024 |
|
| Rhumbline Advisers | 1.5k | $4.2k | 0% | Mar 2024 |
|
| American Capital Advisory | 1.0k | $2.5k | 0% | Mar 2024 |
|
| UBS Group | 932.00 | $2.6k | 0% | Mar 2024 |
|
| McIlrath & Eck | 825.00 | $2.3k | 0% | Mar 2024 |
|
| Us Bancorp | 815.00 | $2.2k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 238.00 | $652.001000 | 2% | Mar 2024 |
|
| Mather Group | 175.00 | $425.005000 | 100% | Mar 2024 |
|
| Householder Group Estate & Retirement Specialist | 150.00 | $411.000000 | 0% | Mar 2024 |
|
| Citigroup | 75.00 | $206.002500 | 0% | Mar 2024 |
|
Who sold out of Athira Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Verition Fund Management | Sep 2023 | 100k | $202k |
| Algert Coldiron Investors | Sep 2023 | 28k | $56k |
| Bank of New York Mellon | Dec 2023 | 16k | $39k |
| Private Advisor | Dec 2023 | 13k | $32k |
| FMR | Sep 2023 | 1.0k | $2.0k |